Downregulation of miR-29 contributes to cisplatin resistance of ovarian cancer cells.
about
Fuling Granule, a Traditional Chinese Medicine Compound, Suppresses Cell Proliferation and TGFβ-Induced EMT in Ovarian CancerMicroRNA-29s could target AKT2 to inhibit gastric cancer cells invasion ability.MicroRNA-18a inhibits ovarian cancer growth via directly targeting TRIAP1 and IPMK.Targeted regulation of MiR-98 on E2F1 increases chemosensitivity of leukemia cells K562/A02.ARID3B increases ovarian tumor burden and is associated with a cancer stem cell gene signatureThe clinicopathological significance of miR-1307 in chemotherapy resistant epithelial ovarian cancer.Identification of miRNA-mRNA regulatory modules by exploring collective group relationships.Clinical validation of chemotherapy predictors developed on global microRNA expression in the NCI60 cell line panel tested in ovarian cancer.Cross disease analysis of co-functional microRNA pairs on a reconstructed network of disease-gene-microRNA tripartite.Combining miRNA and mRNA Expression Profiles in Wilms Tumor Subtypes.Exploring and exploiting the fundamental role of microRNAs in tumor pathogenesis.Prioritizing cancer-related microRNAs by integrating microRNA and mRNA datasets.Efficient Regularized Regression with L0 Penalty for Variable Selection and Network Construction.Overexpression of microRNA-24 increases the sensitivity to paclitaxel in drug-resistant breast carcinoma cell lines via targeting ABCB9.Molecular epigenetics in the management of ovarian cancer: are we investigating a rational clinical promise?Role of microRNAs in cancers of the female reproductive tract: insights from recent clinical and experimental discovery studies.miRNAs as prognostic and therapeutic tools in epithelial ovarian cancer.Epigenetic mechanisms and therapeutic targets of chemotherapy resistance in epithelial ovarian cancer.miRNAs and ovarian cancer: a miRiad of mechanisms to induce cisplatin drug resistance.microRNA and Ovarian Cancer.MiR-129-5p suppresses gastric cancer cell invasion and proliferation by inhibiting COL1A1.c-Myc-miR-29c-REV3L signalling pathway drives the acquisition of temozolomide resistance in glioblastoma.Molecular diagnosis and molecular profiling to detect treatment-resistant ovarian cancer.MicroRNAs in gynecological cancers: Small molecules with big implications.MicroRNA-mediated drug resistance in ovarian cancer.Downregulation of miR-503 contributes to the development of drug resistance in ovarian cancer by targeting PI3K p85.Molecular mechanisms of drug resistance in ovarian cancer.COL1A1 promotes metastasis in colorectal cancer by regulating the WNT/PCP pathway.Tamoxifen differentially regulates miR-29b-1 and miR-29a expression depending on endocrine-sensitivity in breast cancer cells.Comparison of benign peritoneal fluid- and ovarian cancer ascites-derived extracellular vesicle RNA biomarkers.miR‑29a‑3p represses proliferation and metastasis of gastric cancer cells via attenuating HAS3 levels.MicroRNA-142-3p inhibits cell proliferation and chemoresistance in ovarian cancer via targeting sirtuin 1.MiR-29c reduces the cisplatin resistance of non-small cell lung cancer cells by negatively regulating the PI3K/Akt pathway.
P2860
Q28468466-5307F910-F465-4AB1-9607-B44C231039ABQ29347524-DD21AB30-02BC-4BC5-BB46-8ADC1D8AF20CQ33750717-13E2F84D-8F09-42B8-8628-B3F17FBBD064Q33879017-4C2EAED5-88B8-4C8C-8E7B-54F00FD13576Q34483574-B1B70A7F-0B55-4F46-9A1F-E6A90EDE697AQ35666862-59A2DE16-1073-4BA4-8231-6912EE16ADBCQ35905925-DC3BD17A-9A86-4C72-B6F8-83548C14312FQ36320168-506E6E45-9DFA-442A-9F88-DC3943B44600Q36322428-EC29874D-D82D-4FF6-9BBB-0E8865EABEF5Q36846957-DC03D906-7FB4-4C21-9FE7-6C99EEE86137Q37332728-793C1979-15DC-4813-9FB0-831EF7740604Q37335617-50DCA09C-6279-4DDC-AF41-6D647B601BB8Q37397132-B97E950C-501D-443A-A58C-AE972488B599Q37407242-5F6DB3CF-81BC-4A4B-874C-5074D7ADECA3Q37702543-4F1EA29F-5CB8-4312-A353-990A14EC2D5FQ38258014-8DAD42E0-0C3C-44D9-9C83-330288A06CFFQ38366731-0F587F8A-D622-4D83-B2CB-9DC217E0A36DQ38544386-DD006D57-1425-444B-9E2F-7B76B66A0B68Q38633144-1430577A-36D8-4F1E-95FB-8E4B2BFBE8F7Q38667018-349D9BBE-FAF6-40D8-9792-90FED8B6DA82Q38797965-3C25FC42-8296-45EA-AB4F-6CA66C61591FQ38829331-08F50450-7959-4AC3-B2A2-095C00060FE8Q38832323-7D161A59-2DA2-4CCB-8F36-E382408A98BDQ39333266-EBE383BF-B682-48F9-B290-F9A11B03447AQ39382756-BEE80AE3-390E-4639-9F22-E3B0B24E5EB0Q48256677-E32FDE8F-EE21-4123-A3A3-91AD46B7B998Q48274587-153CE6D4-A1D7-4EA7-881C-669338548C74Q49379252-2D48DE79-A017-4ED4-B5EE-4D676E43B61AQ51254914-D1240AAF-21F3-464E-97A7-AA8B2BB8233BQ52676719-57FB2EA7-52E7-4CB7-901D-A67494507BB2Q54964060-3A1D0161-BF3E-459D-9212-261348C4B94EQ55085393-DE3B3132-32AA-424B-BDDE-0826980A6FDFQ55343784-A0874A80-D8D3-4194-A3BA-6226A29E0436
P2860
Downregulation of miR-29 contributes to cisplatin resistance of ovarian cancer cells.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Downregulation of miR-29 contributes to cisplatin resistance of ovarian cancer cells.
@en
Downregulation of miR-29 contributes to cisplatin resistance of ovarian cancer cells.
@nl
type
label
Downregulation of miR-29 contributes to cisplatin resistance of ovarian cancer cells.
@en
Downregulation of miR-29 contributes to cisplatin resistance of ovarian cancer cells.
@nl
prefLabel
Downregulation of miR-29 contributes to cisplatin resistance of ovarian cancer cells.
@en
Downregulation of miR-29 contributes to cisplatin resistance of ovarian cancer cells.
@nl
P2093
P2860
P356
P1476
Downregulation of miR-29 contributes to cisplatin resistance of ovarian cancer cells.
@en
P2093
Hung-Cheng Lai
Li-Tzu Yeh
Ming-De Yan
Pei-Ning Yu
Rui-Lan Huang
Wen-Chi Lin
Ya-Wen Lin
Yu-Ching Chou
P2860
P304
P356
10.1002/IJC.28399
P577
2013-08-28T00:00:00Z